When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

A new class of weight-loss drugs known as GLP-1s are proving to be game changers for people with obesity. They’re also minting billions for pharmaceutical companies, especially the companies that ...

Anticipation builds for Eli Lilly's oral obesity drug orforglipron's trial results in 2025, following Novo Nordisk's ...

Viking Therapeutics (VKTX) is identified by Oppenheimer among five potential biotech M&A candidates ahead of J.P. Morgan Healthcare Conference. Read more here.